Abstract | BACKGROUND: METHODS: RESULTS: Patients with IBD had higher VEGF levels than control subjects (511.5 ± 255.6 versus 395.5 ± 256.4; P = 0.05). Patients who achieved remission at the third dose of anti- TNF-alpha had lower VEGF levels at baseline (453.5 ± 250.7 versus 667.5 ± 153.9 pg/mL) and before the second (409.7 ± 217 versus 681.3 ± 350.6 pg/mL) and third (400.5 ± 222.8 versus 630.4 ± 243.1 pg/mL) doses compared with those with no remission (P < 0.05). Ang1 levels decreased before each treatment dose in patients who achieved remission (P < 0.05). High baseline VEGF levels predicted for a poor response to anti- TNF-alpha therapy (area under the receiver operating characteristics curve = 0.8), whereas high Ang1 levels were associated with disease remission (area under the receiver operating characteristics curve = 0.7). Concentrations of angiogenic proteins did not correlate with clinical activity scores. CONCLUSIONS: Circulating VEGF and Ang1 levels decrease after anti- TNF-alpha therapy and may predict response to treatment. Whether these changes are a direct effect of anti- TNF-alpha therapy or a sign of disease improvement remains to be elucidated.
|
Authors | Alicia Algaba, Pablo M Linares, M Encarnación Fernández-Contreras, Ariadna Figuerola, Xavier Calvet, Iván Guerra, Inés de Pousa, María Chaparro, Javier P Gisbert, Fernando Bermejo |
Journal | Inflammatory bowel diseases
(Inflamm Bowel Dis)
Vol. 20
Issue 4
Pg. 695-702
(Apr 2014)
ISSN: 1536-4844 [Electronic] England |
PMID | 24562175
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiopoietin-1
- Angiopoietin-2
- Anti-Inflammatory Agents, Non-Steroidal
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Infliximab
- Receptor, TIE-2
- Adalimumab
|
Topics |
- Adalimumab
- Adult
- Angiopoietin-1
(blood)
- Angiopoietin-2
(blood)
- Anti-Inflammatory Agents, Non-Steroidal
(pharmacology, therapeutic use)
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Antibodies, Monoclonal, Humanized
(pharmacology, therapeutic use)
- Case-Control Studies
- Colitis, Ulcerative
(blood, drug therapy)
- Crohn Disease
(blood, drug therapy)
- Female
- Humans
- Infliximab
- Male
- Middle Aged
- Predictive Value of Tests
- Prospective Studies
- Receptor, TIE-2
(blood)
- Remission Induction
- Severity of Illness Index
- Vascular Endothelial Growth Factor A
(blood)
- Young Adult
|